Research Insights
NIH: Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders
Supporting projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes.
The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets may not exceed $125,000 per year in direct costs for the R21 phase. Applications may not exceed $250,000 per year in direct costs for the R33 phase.
Letter of intent deadline: 30 days prior to application deadline
Application deadline: June 24, 2019, December 18, 2019, June 24, 2020, December 18, 2020, June 24, 2021, December 17, 2021
More information: https://grants.nih.gov/grants/guide/pa-files/PAR-19-278.html